VINC vs. NMTR, TRVN, EVFM, GRI, APVO, WINT, VIRX, ATXI, SYRS, and BIOR
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include 9 Meters Biopharma (NMTR), Trevena (TRVN), Evofem Biosciences (EVFM), GRI Bio (GRI), Aptevo Therapeutics (APVO), Windtree Therapeutics (WINT), Viracta Therapeutics (VIRX), Avenue Therapeutics (ATXI), Syros Pharmaceuticals (SYRS), and Biora Therapeutics (BIOR). These companies are all part of the "pharmaceutical products" industry.
Vincerx Pharma vs.
Vincerx Pharma (NASDAQ:VINC) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, community ranking, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.
Vincerx Pharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.
Vincerx Pharma presently has a consensus target price of $40.00, indicating a potential upside of 76,090.48%. Given Vincerx Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Vincerx Pharma is more favorable than 9 Meters Biopharma.
Vincerx Pharma's return on equity of -248.33% beat 9 Meters Biopharma's return on equity.
44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Vincerx Pharma had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for 9 Meters Biopharma. Vincerx Pharma's average media sentiment score of 1.89 beat 9 Meters Biopharma's score of 0.00 indicating that Vincerx Pharma is being referred to more favorably in the media.
9 Meters Biopharma received 16 more outperform votes than Vincerx Pharma when rated by MarketBeat users. Likewise, 71.15% of users gave 9 Meters Biopharma an outperform vote while only 65.63% of users gave Vincerx Pharma an outperform vote.
Vincerx Pharma has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
Summary
Vincerx Pharma beats 9 Meters Biopharma on 12 of the 15 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:VINC) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy VINC Stock Free VINC Stock Alerts